|
Summary of secondary endpoints at baseline and week 48 |
|||||||
| Losartan |
Placebo |
||||||
|
|
|||||||
| Baseline (n = 20) |
End of study (n = 16) |
Change |
Baseline (n = 20) |
End of study (n = 18) |
Change |
p-value |
|
|
|
|||||||
| Right atrial pressure (mmHg) |
4.0 (0.8) |
4.0 (0.6) |
-0.1 (1.0) |
4.1 (0.9) |
3.8 (0.0) |
-0.4 (1.0) |
0.56 |
| Peak tricuspid regurgitant velocity (m/s) |
3.3 (0.3) |
3.2 (0.6) |
+0.0 (0.7) |
3.3 (0.4) |
3.5 (0.5) |
+0.2 (0.4) |
0.37 |
| RV systolic pressure (mmHg) |
46.9 (8.9) |
47.3 (14.5) |
+0.7 (16.8) |
47.5 (10.0) |
52.5 (13.4) |
+4.7 (10.9) |
0.41 |
| LV fractional shortening (%) |
33 (8) |
36 (7) |
+2.5 (8.6) |
31 (6) |
32 (9) |
+1.8 (9.7) |
0.84 |
| RV wall thickness (mm) |
4.1 (0.8) |
4.4 (1.3) |
+0.4 (1.1) |
4.0 (0.6) |
4.2 (0.6) |
+0.3 (0.6) |
0.69 |
|
Between group p-value for the difference in change from baseline. LV= left ventricular. RV = right ventricular. | |||||||
Morrell et al. Respiratory Research 2005 6:88 doi:10.1186/1465-9921-6-88 |
|||||||